| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Corey Michael Watton is Director at ZVRA. Corey Michael Watton's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $18K at current prices.
Historically, Corey Michael Watton's trades have earned a below-average insider score of 46/100 across 5 rated trades. Over a 12-month horizon, 40.0% of those trades were profitable, with an average 12-month return of +1.1%.
The ZVRA filings lean toward selling, a net 10,500 shares.
Corey Michael Watton has 10 Form 4 filings on record from May 2023 to August 2026, all as Director at Zevra Therapeutics (ZVRA), 2023–2026.
The 11 reported transactions were 5 open-market purchases, 4 option or other derivative awards, 1 option exercise and 1 open-market sale.
Counted by filing, the open-market trades come to 5 purchases worth about $12K and 1 sale worth about $138K.
The largest open-market purchase was 500 shares of ZVRA at an average $7.92 on October 11, 2024, about $4K. Twelve months later ZVRA was up 35%.
The only open-market sale was 12,300 shares of ZVRA at an average $11.25 on August 10, 2026, about $138K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | ZVRA Zevra Therapeutics, Inc. | Director | Sale+OE | 12,300 | $11.25 | $138,377.46 | -87.2% | - | - | |
| Mar 28, 2025 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 300 | $7.84 | $2,351.52 | +20.0% | +18.2% | +16.7% | |
| Oct 11, 2024 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 500 | $7.92 | $3,957.65 | +50.0% | -0.6% | +34.9% | |
| Jun 23, 2023 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 275 | $5.95 | $1,635.67 | +37.9% | -9.8% | -21.2% | |
| Jun 9, 2023 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 325 | $5.52 | $1,794.00 | +81.3% | -4.5% | -15.8% | |
| May 30, 2023 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 400 | $5.11 | $2,042.12 | New | +1.0% | -9.2% |